These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

228 related items for PubMed ID: 27129439

  • 1. Safety and efficacy of adalimumab treatment in Japanese patients with psoriasis: Results of SALSA study.
    Asahina A, Torii H, Ohtsuki M, Tokimoto T, Hase H, Tsuchiya T, Shinmura Y, Reyes Servin O, Nakagawa H.
    J Dermatol; 2016 Nov; 43(11):1257-1266. PubMed ID: 27129439
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial.
    Kimball AB, Bensimon AG, Guerin A, Yu AP, Wu EQ, Okun MM, Bao Y, Gupta SR, Mulani PM.
    Am J Clin Dermatol; 2011 Feb 01; 12(1):51-62. PubMed ID: 21110526
    [Abstract] [Full Text] [Related]

  • 3. Real-World Postmarketing Study of the Impact of Adalimumab Treatment on Work Productivity and Activity Impairment in Patients with Psoriatic Arthritis.
    Nakagawa H, Tanaka Y, Sano S, Kameda H, Taniguchi A, Kashiwagi T, Kawaberi T, Kimura J, Morita A.
    Adv Ther; 2019 Mar 01; 36(3):691-707. PubMed ID: 30661197
    [Abstract] [Full Text] [Related]

  • 4. Influence of psoriatic arthritis on the efficacy of adalimumab and on the treatment response of other markers of psoriasis burden: subanalysis of the BELIEVE study.
    Paul C, van de Kerkhof P, Puig L, Unnebrink K, Goldblum O, Thaçi D.
    Eur J Dermatol; 2012 Mar 01; 22(6):762-9. PubMed ID: 23178916
    [Abstract] [Full Text] [Related]

  • 5. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
    Spuls PI, Hooft L.
    Br J Dermatol; 2012 Oct 01; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
    [Abstract] [Full Text] [Related]

  • 6. Sleep quality and other patient-reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open-label Phase IIIB trial.
    Strober BE, Sobell JM, Duffin KC, Bao Y, Guérin A, Yang H, Goldblum O, Okun MM, Mulani PM.
    Br J Dermatol; 2012 Dec 01; 167(6):1374-81. PubMed ID: 22897348
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis.
    Menter A, Gordon K, Carey W, Hamilton T, Glazer S, Caro I, Li N, Gulliver W.
    Arch Dermatol; 2005 Jan 01; 141(1):31-8. PubMed ID: 15655139
    [Abstract] [Full Text] [Related]

  • 8. Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis.
    Revicki D, Willian MK, Saurat JH, Papp KA, Ortonne JP, Sexton C, Camez A.
    Br J Dermatol; 2008 Mar 01; 158(3):549-57. PubMed ID: 18047521
    [Abstract] [Full Text] [Related]

  • 9. Safety and effectiveness of apremilast in Japanese patients with psoriatic disease: Results of a post-marketing surveillance study.
    Ohtsuki M, Okubo Y, Saeki H, Igarashi A, Imafuku S, Abe M, Chaudhari S, Yaguchi M, Emoto A, Morita A.
    J Dermatol; 2024 Jul 01; 51(7):950-963. PubMed ID: 38775204
    [Abstract] [Full Text] [Related]

  • 10. Adalimumab treatment optimization for psoriasis: Results of a long-term phase 2/3 Japanese study.
    Asahina A, Ohtsuki M, Etoh T, Gu Y, Okun MM, Teixeira HD, Yamaguchi Y, Nakagawa H.
    J Dermatol; 2015 Nov 01; 42(11):1042-52. PubMed ID: 26118825
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.
    Reich K, Armstrong AW, Foley P, Song M, Wasfi Y, Randazzo B, Li S, Shen YK, Gordon KB.
    J Am Acad Dermatol; 2017 Mar 01; 76(3):418-431. PubMed ID: 28057361
    [Abstract] [Full Text] [Related]

  • 12. Real-world safety and effectiveness of adalimumab in patients with hidradenitis suppurativa: A 52-week analysis of a postmarketing surveillance study in Japan.
    Hayashi N, Hayama K, Takahashi K, Kurokawa I, Okazaki M, Kashiwagi T, Iwashita E, Terui T.
    J Dermatol; 2023 Aug 01; 50(8):1034-1044. PubMed ID: 37264993
    [Abstract] [Full Text] [Related]

  • 13. Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics.
    Papoutsaki M, Chimenti MS, Costanzo A, Talamonti M, Zangrilli A, Giunta A, Bianchi L, Chimenti S.
    J Am Acad Dermatol; 2007 Aug 01; 57(2):269-75. PubMed ID: 17574299
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial.
    Gladman DD, Mease PJ, Ritchlin CT, Choy EH, Sharp JT, Ory PA, Perdok RJ, Sasso EH.
    Arthritis Rheum; 2007 Feb 01; 56(2):476-88. PubMed ID: 17265483
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Adalimumab in severe plaque psoriasis of childhood: A multi-center, retrospective real-life study up to 52 weeks observation.
    Di Lernia V, Bianchi L, Guerriero C, Stingeni L, Gisondi P, Filoni A, Guarneri C, Belloni Fortina A, Lasagni C, Simonetti O, Neri I, Zangrilli A, Moretta G, Hansel K, Casanova DM, Girolomoni G, Cannavò SP, Bonamonte D.
    Dermatol Ther; 2019 Nov 01; 32(6):e13091. PubMed ID: 31579972
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.